Amgen Inc - Company Profile
Powered by
All the data and insights you need on Amgen Inc in one report.
- Save hours of research time and resources with
our up-to-date Amgen Inc Strategy Report
- Understand Amgen Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
View moreAmgen Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Amgen Insights data
Headline | Published | Journalists |
---|---|---|
Deserunt mollit sunt Lorem laborum do id aliqua dolore | 06 Dec 2022 | Lorem |
LoA Update: Amgen’s Next Phase Transition Prospects for Imlygic Increase After Recruitment Restart on Investigator-Led Phase Ib/II Soft Tissue Sarcoma Trial | 13 Oct 2022 | Akosua Mireku |
Mirati Therapeutics’s Adagrasib Faces Likely Approval in NSCLC, But Uptake Hinges on CNS Activity and Safety Profile | 31 Aug 2022 | Adam Zamecnik |
LoA Update: Amgen’s Imlygic Sees Advancement Prospects Drop in Soft Tissue Sarcoma After Investigator-Led Phase Ib/II Trial Suspension | 24 Aug 2022 | Urte Fultinaviciute |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer